Media

Oncopeptides announces that the first patients in the United States are being treated with PEPAXTO®

Vicore Pharma’s drug candidate C21 dilates peripheral resistance vessels in fibrotic disease

Oncopeptides has completed a directed share issue raising approximately SEK 1,106 million (USD 130 million)

Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma

Press release from the extraordinary general meeting of Vicore Pharma Holding AB (publ)

Strongbridge Biopharma plc Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update

Pulmonx Reports Fourth Quarter and Full Year 2020 Financial Results

Strongbridge Biopharma plc Announces Submission of New Drug Application for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to the U.S. Food & Drug Administration

Fusion Pharmaceuticals To Expand Pipeline With Acquisition Of IPN-1087, A Small Molecule Targeting NTSR1, From Ipsen